{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:49:46Z","timestamp":1782917386124,"version":"3.54.5"},"reference-count":33,"publisher":"Scientific Scholar","content-domain":{"domain":["ijmr.org.in"],"crossmark-restriction":true},"short-container-title":["Indian J Med Res"],"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Stem cell therapy has emerged as a potential treatment for type 1 diabetes mellitus (T1DM), offering the possibility of modifying disease progression. This systematic review and meta-analysis aimed to assess the efficacy and safety of stem cell therapy in patients with T1DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Embase, Web of Science, and CENTRAL for randomised controlled trials (RCTs) published until January 2025 that evaluated stem cell therapy in T1DM. The primary outcome was the glycated haemoglobin (HbA1c) level. The secondary outcomes included fasting C-peptide levels, insulin dose reduction, insulin independence, and adverse events. The risk of bias was assessed using the Risk of Bias 2.0 tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight reports from seven RCTs (169 participants) were included. Stem cell therapy was associated with a marginal reduction in HbA1c at 6 months [mean difference (MD): -0.57%, 95% CI: -1.13 to -0.02] but not at 12 months (-0.49%, -0.98 to 0.00). Fasting C-peptide levels (ng\/mL) showed slight improvement at both 6 months (0.03, 0.03 to 0.03) and 12 months (0.09, 0.05 to 0.13). None of the participants achieved insulin independence or experienced serious adverse events. The certainty of the evidence was rated as very low for all outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation and conclusions<\/jats:title>\n                    <jats:p>Stem cell therapy may offer marginal improvements in HbA1c and fasting C-peptide levels in T1DM; however, these benefits are of limited clinical significance. Given the small sample sizes, high heterogeneity, and very low certainty of evidence, well-designed, adequately powered RCTs are required to establish the therapeutic role of stem cells in T1DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.25259\/ijmr_2655_2025","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:24:47Z","timestamp":1782908687000},"page":"81-90","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of stem cell therapy in type 1 diabetes: A systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.25259","volume":"164","author":[{"given":"Jaivinder","family":"Yadav","sequence":"first","affiliation":[{"name":"Department of Pediatrics (Advanced Pediatrics Centre), Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jogender","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (Advanced Pediatrics Centre), Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (Advanced Pediatrics Centre), Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesa","family":"Dawman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (Advanced Pediatrics Centre), Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra","family":"Meena","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokesh","family":"Saini","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijaya","family":"Kumar Padhi","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devi","family":"Dayal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (Advanced Pediatrics Centre), Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimesh","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"10.25259\/IJMR_2655_2025\/ref-1","volume-title":"IDF Diabetes Atlas 11th Edition Scientific Committee. IDF Diabetes Atlas","author":"Magliano","year":"2025","edition":"11th ed"},{"key":"10.25259\/IJMR_2655_2025\/ref-2","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/pedi.13428","article-title":"ISPAD clinical practice consensus guidelines 2022: Psychological care of children, adolescents and young adults with diabetes","volume":"23","author":"De Wit","year":"2022","journal-title":"Pediatr Diabetes."},{"key":"10.25259\/IJMR_2655_2025\/ref-3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med."},{"key":"10.25259\/IJMR_2655_2025\/ref-4","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","article-title":"Teplizumab and \u03b2-cell function in newly diagnosed type 1 diabetes","volume":"389","author":"Ramos","year":"2023","journal-title":"N Engl J Med."},{"key":"10.25259\/IJMR_2655_2025\/ref-5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrendo.2009.274","article-title":"Stem cell therapy for type 1 diabetes mellitus","volume":"6","author":"Aguayo-Mazzucato","year":"2010","journal-title":"Nat Rev Endocrinol."},{"key":"10.25259\/IJMR_2655_2025\/ref-6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.5966\/sctm.2012-0116","article-title":"Stem cell therapy to cure type 1 diabetes: From hype to hope","volume":"2","author":"Chhabra","year":"2013","journal-title":"Stem Cells Transl Med."},{"key":"10.25259\/IJMR_2655_2025\/ref-7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13287-024-03636-0","article-title":"Current status of stem cell therapy for type 1 diabetes: A critique and a prospective consideration","volume":"15","author":"Ghoneim","year":"2024","journal-title":"Stem Cell Res Ther."},{"key":"10.25259\/IJMR_2655_2025\/ref-8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s44324-024-00014-5","article-title":"Finishing the odyssey to a stem cell cure for type 1 diabetes","volume":"2","author":"Hunault","year":"2024","journal-title":"NPJ Metab Health Dis."},{"key":"10.25259\/IJMR_2655_2025\/ref-9","doi-asserted-by":"publisher","first-page":"e075681","DOI":"10.1136\/bmj-2023-075681","article-title":"New advances in type 1 diabetes","volume":"384","author":"Subramanian","year":"2024","journal-title":"BMJ."},{"key":"10.25259\/IJMR_2655_2025\/ref-10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13643-022-01950-3","article-title":"Investigating the safety and efficacy of hematopoietic and mesenchymal stem cell transplantation for treatment of T1DM: A systematic review and meta-analysis","volume":"11","author":"Madani","year":"2022","journal-title":"Syst Rev."},{"key":"10.25259\/IJMR_2655_2025\/ref-11","doi-asserted-by":"publisher","first-page":"101740","DOI":"10.1016\/j.trim.2022.101740","article-title":"Clinical efficacy of stem-cell therapy on diabetes mellitus: A systematic review and meta-analysis","volume":"75","author":"Pires","year":"2022","journal-title":"Transpl Immunol."},{"key":"10.25259\/IJMR_2655_2025\/ref-12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jcyt.2021.09.015","article-title":"Prevention of chronic diabetic complications in type 1 diabetes by co-transplantation of umbilical cord mesenchymal stromal cells and autologous bone marrow: A pilot randomized controlled open-label clinical study with 8-year follow-up","volume":"24","author":"Wu","year":"2022","journal-title":"Cytotherapy."},{"key":"10.25259\/IJMR_2655_2025\/ref-13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13287-022-02941-w","article-title":"Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: A phase i\/II randomized placebo-controlled clinical trial","volume":"13","author":"Izadi","year":"2022","journal-title":"Stem Cell Res Ther."},{"key":"10.25259\/IJMR_2655_2025\/ref-14","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00125-023-05934-3","article-title":"Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: A Phase i\/II randomised double-blind placebo-controlled trial","volume":"66","author":"Carlsson","year":"2023","journal-title":"Diabetologia."},{"key":"10.25259\/IJMR_2655_2025\/ref-15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"10.25259\/IJMR_2655_2025\/ref-16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/pedi.12773","article-title":"ISPAD Clinical Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents","volume":"19","author":"Mayer-Davis","year":"2018","journal-title":"Pediatr Diabetes."},{"key":"10.25259\/IJMR_2655_2025\/ref-17","doi-asserted-by":"publisher","first-page":"e00750","DOI":"10.1002\/prp2.750","article-title":"Alignment between outcomes and minimal clinically important differences in the Dutch type 2 diabetes mellitus guideline and healthcare professionals\u2019 preferences","volume":"9","author":"Dankers","year":"2021","journal-title":"Pharmacol Res Perspect."},{"key":"10.25259\/IJMR_2655_2025\/ref-18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s13300-017-0265-4","article-title":"A practical review of C-peptide testing in diabetes","volume":"8","author":"Leighton","year":"2017","journal-title":"Diabetes Ther."},{"key":"10.25259\/IJMR_2655_2025\/ref-19","doi-asserted-by":"publisher","first-page":"e081903","DOI":"10.1136\/bmj-2024-081903","article-title":"Core GRADE 1: Overview of the core GRADE approach","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ."},{"key":"10.25259\/IJMR_2655_2025\/ref-20","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.bbmt.2013.04.011","article-title":"Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with type 1 diabetes","volume":"19","author":"Haller","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.25259\/IJMR_2655_2025\/ref-21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1507\/endocrj.ej12-0343","article-title":"Long term effects of the implantation of Wharton\u2019s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus","volume":"60","author":"Hu","year":"2013","journal-title":"Endocr J."},{"key":"10.25259\/IJMR_2655_2025\/ref-22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2337\/db14-0656","article-title":"Preserved b-cell function in type 1 diabetes by mesenchymal stromal cells","volume":"64","author":"Carlsson","year":"2015","journal-title":"Diabetes."},{"key":"10.25259\/IJMR_2655_2025\/ref-23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2337\/dc15-0171","article-title":"Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: A pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion","volume":"39","author":"Cai","year":"2016","journal-title":"Diabetes Care."},{"key":"10.25259\/IJMR_2655_2025\/ref-24","first-page":"541","article-title":"The effect of fetal liver-derived cell suspension allotransplantation on patients with diabetes: First year of follow-up","volume":"50","author":"Ghodsi","year":"2012","journal-title":"Acta Med Iran."},{"key":"10.25259\/IJMR_2655_2025\/ref-25","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med."},{"key":"10.25259\/IJMR_2655_2025\/ref-26","doi-asserted-by":"publisher","first-page":"CD009122","DOI":"10.1002\/14651858.CD009122.pub2","article-title":"Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus","volume":"2014","author":"Fullerton","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"10.25259\/IJMR_2655_2025\/ref-27","doi-asserted-by":"publisher","first-page":"e0247662","DOI":"10.1371\/journal.pone.0247662","article-title":"Clinical efficacy on glycemic control and safety of mesenchymal stem cells in patients with diabetes mellitus: Systematic review and meta-analysis of RCT data","volume":"16","author":"He","year":"2021","journal-title":"PLoS One."},{"key":"10.25259\/IJMR_2655_2025\/ref-28","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s13287-020-01996-x","article-title":"Therapeutic efficacy of umbilical cord-derived stem cells for diabetes mellitus: A meta-analysis study","volume":"11","author":"Kassem","year":"2020","journal-title":"Stem Cell Res Ther."},{"key":"10.25259\/IJMR_2655_2025\/ref-29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1089\/scd.2016.0275","article-title":"Efficacy of autologous bone marrow-derived mesenchymal stem cell and mononuclear cell transplantation in type 2 diabetes mellitus: A randomized, placebo-controlled comparative study","volume":"26","author":"Bhansali","year":"2017","journal-title":"Stem Cells Dev."},{"key":"10.25259\/IJMR_2655_2025\/ref-30","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3727\/096368913X665576","article-title":"Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus: A randomized placebo-controlled study","volume":"23","author":"Bhansali","year":"2014","journal-title":"Cell Transplant."},{"key":"10.25259\/IJMR_2655_2025\/ref-31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13287-022-02848-6","article-title":"Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: A single-center, double-blinded, randomized, placebo-controlled phase II trial","volume":"13","author":"Zang","year":"2022","journal-title":"Stem Cell Res Ther."},{"key":"10.25259\/IJMR_2655_2025\/ref-32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40200-014-0126-x","article-title":"Evaluation of fetal cell transplantation safety in treatment of diabetes: A three-year follow-up","volume":"14","author":"Nasli-Esfahani","year":"2015","journal-title":"J Diabetes Metab Disord."},{"key":"10.25259\/IJMR_2655_2025\/ref-33","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1681\/ASN.0000000000000189","article-title":"Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-m) therapy in diabetic kidney disease: A randomized clinical trial (NEPHSTROM)","volume":"34","author":"Perico","year":"2023","journal-title":"J Am Soc Nephrol."}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ijmr.org.in\/efficacy-and-safety-of-stem-cell-therapy-in-type-1-diabetes-a-systematic-review-and-meta-analysis-of-randomised-controlled-trials\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ijmr.org.in\/efficacy-and-safety-of-stem-cell-therapy-in-type-1-diabetes-a-systematic-review-and-meta-analysis-of-randomised-controlled-trials\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:01:09Z","timestamp":1782914469000},"score":1,"resource":{"primary":{"URL":"http:\/\/ijmr.org.in\/efficacy-and-safety-of-stem-cell-therapy-in-type-1-diabetes-a-systematic-review-and-meta-analysis-of-randomised-controlled-trials\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":33,"alternative-id":["10.25259\/IJMR_2655_2025"],"URL":"https:\/\/doi.org\/10.25259\/ijmr_2655_2025","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"81"}}